Replies to post #142053 on Biotech Values

[NP1986]

Have you had a chance to look at the ibrutinib abstracts?

[genisi]

ONXX/carfilzomib in MM

I think the ONXX MM data will be quite helpful for them with the FDA. They show some clear responses (about 20% PRs or better with an 8 month duration) in patients refractory to any and all available therapies.

Data are good in general, but note that most data are for refractory/intolerant patients, who are not "real" refractory ones, rather they are refractory or intolerant. Intolerant patients tend to have better response rates plus they might still have other treatment option. The only data for patients "Refractory to all approved tx" come from a 44 patients group with ORR=20.5 so very few responders.

http://abstract.asco.org/AbstView_114_94418.html